Jaguar Health, Inc. (JAGX) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
0.03
↓-91% vs avg
5yr avg: 0.38
30Y Low0.4·High0.4
P/B Ratio
↑
N/A
—
5yr avg: 0.69
30Y Low0.2·High1.1
ROE
↓
N/A
—
5yr avg: -1068.7%
30Y Low-480%·High-243%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
JAGX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Jaguar Health, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 0.0x P/FCF, 91% below the 5-year average of 0.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $187925 | $2M | $7M | $1M | — | — | — | — | — | — | — |
| Enterprise Value | $43M | $45M | $36M | $32M | — | — | — | — | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.02 | 0.19 | 0.64 | 0.12 | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 1.15 | 0.24 | — | — | — | — | — | — | — |
| P/FCF | 0.03 | 0.38 | — | — | — | — | — | — | — | — | — |
| P/OCF | 0.03 | 0.37 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
JAGX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.89 | 3.08 | 3.26 | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 7.76 | — | — | — | — | — | — | — | — | — |
JAGX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Jaguar Health, Inc. earns an operating margin of -398.8%. Operating margins have compressed from -351.3% to -398.8% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.2% | 67.2% | 83.3% | 79.1% | 83.1% | 46.2% | 65.1% | 33.9% | 37.4% | 79.8% | 63.3% |
| Operating Margin | -398.8% | -398.8% | -263.8% | -351.3% | -287.8% | -939.1% | -283.9% | -501.3% | -698.0% | -785.3% | -9599.8% |
| Net Profit Margin | -465.4% | -465.4% | -329.3% | -423.1% | -396.9% | -1213.3% | -360.2% | -667.3% | -727.9% | -503.7% | -10410.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -675.8% | -2332.7% | -904.1% | -362.0% | -242.6% | -480.1% | -283.9% | -296.7% | -1515.1% |
| ROA | -116.8% | -116.8% | -73.9% | -84.1% | -94.2% | -109.4% | -85.3% | -99.5% | -75.9% | -93.1% | -184.5% |
| ROIC | -116.8% | -116.8% | -65.6% | -81.0% | -98.9% | -123.4% | -99.8% | -129.1% | -88.8% | -152.8% | -649.7% |
| ROCE | -292.5% | -292.5% | -87.5% | -127.3% | -125.4% | -120.8% | -105.2% | -163.5% | -144.6% | -248.0% | -345.4% |
JAGX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $43M ($44M total debt minus $968000 cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 5.62 | 7.57 | — | 2.48 | 0.94 | 0.71 | 2.99 | 0.95 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 4.39 | 6.25 | — | 1.04 | 0.47 | 0.38 | 2.51 | 0.92 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 7.39 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -565.60 | -565.60 | -168.92 | -5.31 | -2.80 | -5.25 | -11.11 | -5.72 | -11.23 | -12.50 | -13.79 |
JAGX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.50x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 2.00x to 0.50x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.50 | 0.50 | 1.63 | 2.00 | 0.74 | 1.84 | 1.35 | 0.62 | 0.31 | 0.25 | 0.61 |
| Quick Ratio | 0.29 | 0.29 | 1.11 | 1.34 | 0.50 | 1.52 | 1.14 | 0.48 | 0.18 | 0.11 | 0.51 |
| Cash Ratio | 0.02 | 0.02 | 0.41 | 0.46 | 0.18 | 1.10 | 0.61 | 0.23 | 0.10 | 0.03 | 0.23 |
| Asset Turnover | — | 0.30 | 0.22 | 0.19 | 0.25 | 0.08 | 0.22 | 0.16 | 0.11 | 0.10 | 0.04 |
| Inventory Turnover | 0.44 | 0.44 | 0.19 | 0.22 | 0.29 | 0.48 | 1.18 | 1.79 | 0.83 | 0.42 | 0.13 |
| Days Sales Outstanding | — | 53.84 | 51.43 | 81.67 | 75.31 | 180.52 | 177.35 | 107.07 | 82.80 | 39.26 | 785.62 |
JAGX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Jaguar Health, Inc. returns 100.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 100.0% | 265.8% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 100.0% | 100.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 100.0% | 100.0% | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $66640 | $8415 | $441 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Peer Comparison
Compare JAGX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 JAGXYou | $187925 | -0.0 | — | 0.0 | 67.2% | -398.8% | — | -116.8% | — |
 PRGO | $2B | -1.2 | 7.5 | 11.6 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 PAHC | $2B | 49.3 | 19.7 | 56.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 SUPN | $3B | -75.7 | 52.6 | 64.4 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 IRWD | $788M | 32.2 | 9.7 | 6.2 | 99.4% | 40.1% | — | 54.0% | 5.0 |
 PTGX | $7B | -50.7 | — | 118.3 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 ARRY | $1B | -11.1 | 13.4 | 15.6 | 21.2% | 6.6% | -19.0% | 9.0% | 5.8 |
 ACAD | $4B | 9.4 | 25.6 | 35.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 VNDA | $440M | -2.0 | — | — | 94.0% | -70.0% | -50.9% | -32.2% | — |
 MCK | $91B | 28.9 | 18.5 | 17.4 | 3.5% | 1.2% | — | 540.6% | 1.5 |
 CAH | $45B | 29.7 | 16.5 | 24.4 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
See JAGX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs JAGX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare JAGX vs PRGO
Side-by-side business, growth, and profitability comparison vs Perrigo Company plc.
Start ComparisonJAGX — Frequently Asked Questions
Quick answers to the most common questions about buying JAGX stock.
What is Jaguar Health, Inc.'s P/E ratio?
Jaguar Health, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Is JAGX stock overvalued?
Based on historical data, Jaguar Health, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Jaguar Health, Inc.'s profit margins?
Jaguar Health, Inc. has 67.2% gross margin and -398.8% operating margin.